MGNX

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies primarily for oncology, hematology, and autoimmune diseases. The company advances a diverse pipeline of novel product candidates and utilizes various platform technologies, including antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers. MacroGenics collaborates with global biopharmaceutical partners to bring its therapies to market.